Does Hereditary multiple exostoses have a cure?

Currently, there is no medical or surgical cure for Hereditary multiple exostoses (HME), as it is a genetic condition characterized by the growth of multiple benign bone tumors. While a permanent reversal of the underlying genetic mutation is not yet available, current treatments focus on effective symptom management, surgical intervention for complications, and monitoring to prevent the rare risk of malignant transformation.

What is the current standard of care for Hereditary multiple exostoses?

Because there is no cure for Hereditary multiple exostoses, treatment plans are personalized based on the location and severity of the exostoses (bony outgrowths). The primary goal is to preserve function and alleviate pain. Patients often work with a multidisciplinary team, including orthopedic surgeons, geneticists, and physical therapists. Surgical excision is typically reserved for cases where the growths cause nerve compression, restricted joint mobility, significant deformity, or persistent pain. For the 266 members of our DiseaseMaps community living with Hereditary multiple exostoses, ongoing monitoring through regular imaging—such as X-rays, CT scans, or MRIs—is essential to track growth and ensure that none of the exostoses show signs of secondary chondrosarcoma, which occurs in approximately 1% to 5% of adult patients.

What research is being conducted to find a cure?

Research into Hereditary multiple exostoses is shifting from purely symptomatic management toward understanding the underlying molecular pathways. HME is caused by mutations in the EXT1 or EXT2 genes, which disrupt the synthesis of heparan sulfate. Current scientific investigations are exploring several high-potential avenues:

• Precision Medicine: Researchers are investigating small molecule therapies that may modulate the signaling pathways affected by the loss of heparan sulfate.


• Gene Therapy: While still in early preclinical stages, gene editing technologies like CRISPR-Cas9 are being studied in laboratory models to determine if the function of the EXT genes can be restored.


• Inhibitor Studies: Scientists are looking at pharmacological agents that might stabilize or slow the growth of exostoses in pediatric patients, potentially reducing the need for repeated surgeries.

Are there clinical trials available for Hereditary multiple exostoses?

While no large-scale clinical trials have yet yielded a definitive "cure" for Hereditary multiple exostoses, the landscape of rare disease research is moving faster than ever. Current clinical trial efforts are often focused on natural history studies, which are critical for gathering the data necessary to design future drug trials. Participating in a patient registry or a natural history study helps researchers understand the variability of Hereditary multiple exostoses across different populations, which is a vital step toward future therapeutic breakthroughs.

How can patients stay informed about research progress?

Staying connected with the scientific community is the best way to track advancements in the treatment of Hereditary multiple exostoses. We recommend the following strategies for patients and caregivers:

• Monitor the NIH Genetic and Rare Diseases (GARD) Information Center for updates on new research initiatives.


• Engage with specialized patient advocacy organizations, such as the MHE Research Foundation, which fund and promote clinical research.


• Consult with a genetic counselor or an orthopedic oncologist at a major academic medical center to discuss if you are a candidate for any emerging clinical registries.


• Regularly check ClinicalTrials.gov using "Hereditary multiple exostoses" as your search term to view active or recruiting studies.

Next steps

• Schedule a consultation with an orthopedic surgeon experienced in skeletal dysplasias to establish a baseline monitoring plan.


• Join the Hereditary multiple exostoses community on DiseaseMaps.org to share experiences and learn from others navigating the same diagnostic and treatment journey.


• Speak with a geneticist to understand your specific EXT1 or EXT2 mutation and how it may inform your long-term health monitoring.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Hereditary multiple exostoses (ORPHA:323).


• NIH Genetic and Rare Diseases (GARD) Information Center: Hereditary Multiple Exostoses.


• OMIM (Online Mendelian Inheritance in Man): Multiple Exostoses, Hereditary, 1 (EXT1).


• MHE Research Foundation: Supporting research and patient advocacy for HME.